🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonis...
Status
Completed
Location
GSK Investigational Site
Start Date
2016-06-23
Trial ID
NCT02723955
This phase I/II trial studies the best dose and side effects of mogamulizum...
Status
Completed
Location
University of California Davis Comprehensive Cancer Center
Start Date
2018-10-24
Trial ID
NCT03309878
Treatments Being Tested
The purpose of this study is to evaluate the safety and efficacy of pembrol...
Status
Completed
Location
St Joseph Heritage Healthcare-Oncology ( Site 0004)
Start Date
2021-10-07
Trial ID
NCT05008224
The Phase I trial is evaluating safety, tolerability, pharmacokinetics and ...
Status
Recruiting
Location
Herlev and Gentofte Hospital, Center for Cancer Research
Start Date
2021-04-12
Trial ID
NCT04855435
Treatments Being Tested
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-a...
Status
Terminated
Location
MD Anderson Cancer Center
Start Date
2018-11-20
Trial ID
NCT02842125
The purpose of this first-in-human study is to evaluate the safety, tolerab...
Status
Recruiting
Location
City of Hope National Medical Center
Start Date
2025-07-31
Trial ID
NCT07094113
Treatments Being Tested
This phase I/II trial studies the side effects of pembrolizumab and vorinos...
Status
Completed
Location
Fred Hutch/University of Washington Cancer Consortium
Start Date
2015-10-08
Trial ID
NCT02538510
Treatments Being Tested
This study consists of Part A for monotherapy and Part B for combination th...
Status
Recruiting
Location
NEXT Oncology
Start Date
2021-12-02
Trial ID
NCT05204862
Treatments Being Tested
This study is a Phase I/II, multicenter, first-in-human, open-label dose-es...
Status
Active Not Recruiting
Location
Sarah Cannon Research Institute at HealthONE
Start Date
2020-07-17
Trial ID
NCT04561362
Treatments Being Tested
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study...
Status
Recruiting
Location
Massachusetts General Hospital
Start Date
2024-12-11
Trial ID
NCT06724016
Treatments Being Tested